The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their ...

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel ...

These soluble protein agonists can replicate Notch activation in suspension culture, opening the door to scalable T-cell therapies.

Background: AML impairs immunosurveillance bypassing target recognition and subsequent cytotoxic T cell responses. Immunomodulatory and cytotoxic effects of AV and γδTCA with ICT01 have shown ...

TCEs promote the crosslinking of T cells with tumor cells by simultaneously binding to CD3 on T cells and BCMA on MM cells. This triggers the activation of T cells, releasing cytotoxic factors to ...

In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Quiver AI Summary Zymeworks Inc ...

Treating cultured T cells with the engineered proteins did not have a detrimental effect on T cell function, but induced LCK enzyme activity. From the collection of engineered proteins, the ...

T cells exhibit remarkable plasticity in the tumor microenvironment (TME), dynamically adapting their phenotypes and functions to influence cancer progression and treatment responses. A new review ...

Protein complexes that adorn the surface of T cells—T cell receptors (TCRs)—act like molecular patrol officers, scanning cells for potential threats. When these receptors recognize short peptide ...